• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部鳞状细胞癌中细胞周期蛋白D1的扩增以及染色体异常和细胞周期蛋白D1过表达的预后价值。

Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.

作者信息

Akervall J A, Michalides R J, Mineta H, Balm A, Borg A, Dictor M R, Jin Y, Loftus B, Mertens F, Wennerberg J P

机构信息

Department of Otorhinolaryngology/Head and Neck Surgery, University Hospital, Lund, Sweden.

出版信息

Cancer. 1997 Jan 15;79(2):380-9.

PMID:9010112
Abstract

BACKGROUND

Abnormalities of chromosome band 11q13 are frequent in squamous cell carcinoma of the head and neck (SCCHN). The oncogene CCND1 is located at 11q13 and encodes cyclin D1, a cell cycle-regulating protein. The authors investigated the clinical relevance and associations between amplification and overexpression of cyclin D1 and 11q13 rearrangements.

METHODS

The study involved two series of patients. In Series 1, overexpression of cyclin D1 and 11q13 rearrangements, assessed by immunohistochemistry and cytogenetics, respectively, were compared with clinical data in 75 patients with SCCHN. Patients were monitored for at least 18 months or until death. In another 23 patients (Series 2), the authors investigated the association between DNA amplification (by slot blot hybridization), overexpression of cyclin D1, and cytogenetics.

RESULTS

In Series 1, 9 of 75 tumors (12%) had 11q13 aberrations, 6 of which manifested elevated expression of cyclin D1. Patients with tumors strongly positive for cyclin D1 (n = 9) and those with tumors showing 11q13 rearrangements had poorer survival (P = 0.047 and 0.005, respectively). However, the correlation between these two variables was weak (P = 0.12). In Series 2, 17 of 23 tumors (74%) showed elevated cyclin D1 protein expression, and 6 of these showed gene amplification as well. Of these six, only one revealed 11q13 rearrangements.

CONCLUSIONS

Overexpression of cyclin D1 and 11q13 rearrangements are independent prognostic factors for SCCHN. In general, DNA amplification results in overexpression of cyclin D1, but additional genetic mechanisms are involved in the deregulation. Furthermore, oncogenes at 11q13 besides CCND1 may be involved in the tumorigenesis.

摘要

背景

11q13染色体异常在头颈部鳞状细胞癌(SCCHN)中很常见。癌基因CCND1位于11q13,编码细胞周期调节蛋白细胞周期蛋白D1。作者研究了细胞周期蛋白D1的扩增和过表达与11q13重排之间的临床相关性及关联。

方法

该研究纳入了两组患者。在第一组中,分别通过免疫组织化学和细胞遗传学评估的细胞周期蛋白D1过表达和11q13重排与75例SCCHN患者的临床数据进行了比较。对患者进行了至少18个月的监测或直至死亡。在另外23例患者(第二组)中,作者研究了DNA扩增(通过斑点杂交)、细胞周期蛋白D1过表达与细胞遗传学之间的关联。

结果

在第一组中,75个肿瘤中有9个(12%)存在11q13畸变,其中6个表现为细胞周期蛋白D1表达升高。细胞周期蛋白D1强阳性的肿瘤患者(n = 9)和显示11q13重排的肿瘤患者的生存率较低(分别为P = 0.047和0.005)。然而,这两个变量之间的相关性较弱(P = 0.12)。在第二组中,23个肿瘤中有17个(74%)显示细胞周期蛋白D1蛋白表达升高,其中6个也显示基因扩增。在这6个中,只有1个显示11q13重排。

结论

细胞周期蛋白D1过表达和11q13重排是SCCHN的独立预后因素。一般来说,DNA扩增导致细胞周期蛋白D1过表达,但还涉及其他遗传机制的失调。此外,11q13上除CCND1之外的癌基因可能参与肿瘤发生。

相似文献

1
Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.头颈部鳞状细胞癌中细胞周期蛋白D1的扩增以及染色体异常和细胞周期蛋白D1过表达的预后价值。
Cancer. 1997 Jan 15;79(2):380-9.
2
Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.涉及11q13的染色体易位导致头颈部鳞状细胞癌中细胞周期蛋白D1的过表达。
Int J Oncol. 2002 Jan;20(1):45-52.
3
PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas.PRAD-1/细胞周期蛋白D1基因扩增与人类喉癌中的信使核糖核酸过表达及肿瘤进展相关。
Cancer Res. 1994 Sep 1;54(17):4813-7.
4
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.细胞周期蛋白D1扩增和p16(MTS1/CDK4I)缺失与头颈部肿瘤的不良预后相关。
Laryngoscope. 2002 Mar;112(3):472-81. doi: 10.1097/00005537-200203000-00013.
5
Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification.头颈部肿瘤发生早期细胞周期蛋白D1表达失调:与后续基因扩增相关的体内证据
Oncogene. 1998 Nov 5;17(18):2313-22. doi: 10.1038/sj.onc.1202153.
6
A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification.口腔鳞状细胞癌细胞系中RIN1重排的一致模式支持11q13扩增的断裂-融合-桥循环模型。
Genes Chromosomes Cancer. 2000 Jun;28(2):153-63.
7
Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.在一组47例可手术切除的头颈部鳞状细胞癌中,细胞周期蛋白D1的过表达与复发相关。
Cancer Res. 1995 Mar 1;55(5):975-8.
8
Cyclin D1 abnormalities and tobacco exposure in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中的细胞周期蛋白D1异常与烟草暴露
Head Neck. 1996 Nov-Dec;18(6):512-21. doi: 10.1002/(SICI)1097-0347(199611/12)18:6<512::AID-HED5>3.0.CO;2-5.
9
Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.细胞周期蛋白D1(PRAD1)在乳腺癌中的蛋白表达:约三分之一的浸润性乳腺癌显示细胞周期蛋白D1癌基因过表达。
Mod Pathol. 1995 Jun;8(5):560-7.
10
Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.细胞周期蛋白D1扩增与原发性乳腺癌患者总生存期的降低无关,但可能预示着预后良好特征患者的早期复发。
Clin Cancer Res. 1996 Jul;2(7):1177-84.

引用本文的文献

1
Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging.用于脑和癌症 PET 成像的放射性标记细胞周期蛋白依赖性激酶 4 和 6(CDK4/6)抑制剂的开发。
Int J Mol Sci. 2024 Jun 22;25(13):6870. doi: 10.3390/ijms25136870.
2
Prognostic Significance of Proliferative Markers: Cyclin D1 and CENPF in Oral Squamous Cell Carcinoma Patients-A Cohort Study.增殖标志物细胞周期蛋白D1和着丝粒蛋白F在口腔鳞状细胞癌患者中的预后意义:一项队列研究
J Maxillofac Oral Surg. 2023 Sep;22(3):734-740. doi: 10.1007/s12663-023-01884-w. Epub 2023 Mar 16.
3
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation.
癌组织中细胞周期蛋白 D1 剪接异常:从分子机制到治疗调控。
Cell Death Dis. 2023 Apr 6;14(4):244. doi: 10.1038/s41419-023-05763-7.
4
Degradation strategy of cyclin D1 in cancer cells and the potential clinical application.癌细胞中细胞周期蛋白D1的降解策略及其潜在临床应用。
Front Oncol. 2022 Aug 18;12:949688. doi: 10.3389/fonc.2022.949688. eCollection 2022.
5
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.细胞周期蛋白与细胞周期蛋白依赖性激酶:从生物学特性到肿瘤发生及治疗机遇
J Cancer Res Clin Oncol. 2023 Apr;149(4):1585-1606. doi: 10.1007/s00432-022-04135-6. Epub 2022 Jul 4.
6
Potential Role of Epstein-Barr Virus in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma: A Scoping Review.EB 病毒在口腔潜在恶性疾病和口腔鳞状细胞癌中的潜在作用:范围综述。
Viruses. 2022 Apr 13;14(4):801. doi: 10.3390/v14040801.
7
Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.药物抑制共济失调毛细血管扩张症突变基因与 Rad3 相关蛋白(ATR)在头颈部鳞状细胞癌治疗中的应用。
Mol Carcinog. 2022 Feb;61(2):225-238. doi: 10.1002/mc.23384. Epub 2021 Dec 29.
8
Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.乳腺癌中 CDK4/6 激活的无创性 PET 成像。
J Nucl Med. 2020 Mar;61(3):437-442. doi: 10.2967/jnumed.119.232603. Epub 2019 Sep 3.
9
Treating cancer with selective CDK4/6 inhibitors.用选择性 CDK4/6 抑制剂治疗癌症。
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31.
10
Biomarkers of head and neck cancer, tools or a gordian knot?头颈癌的生物标志物:工具还是难解之结?
Int J Clin Exp Med. 2015 Jul 15;8(7):10340-57. eCollection 2015.